Capstone Investment Advisors
REGN icon

Capstone Investment Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Capstone Investment Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.32M Buy
4,300
+3,100
+258% +$2.37M 0.01% 510
2025
Q4 		$926K Hold
1,200
– – ﹤0.01% 895
2025
Q3 		$675K Hold
1,200
– – ﹤0.01% 1197
2025
Q2 		$630K Buy
+1,200
New +$670K ﹤0.01% 1041
2025
Q1 		– Sell
-4,000
Closed -$2.85M – 1782
2024
Q4 		$2.85M Sell
4,000
-300
-7% -$252K 0.01% 730
2024
Q3 		$4.52M Sell
4,300
-600
-12% -$668K 0.01% 488
2024
Q2 		$5.15M Buy
4,900
+3,700
+308% +$3.59M 0.02% 453
2024
Q1 		$1.15M Sell
1,200
-900
-43% -$856K ﹤0.01% 1062
2023
Q4 		$1.84M Buy
2,100
+1,500
+250% +$1.24M 0.01% 830
2023
Q3 		$494K Hold
600
– – ﹤0.01% 1332
2023
Q2 		$431K Hold
600
– – ﹤0.01% 1220
2023
Q1 		$493K Sell
600
-2,400
-80% -$1.81M ﹤0.01% 1016
2022
Q4 		$2.16M Buy
3,000
+100
+3% +$73.8K 0.02% 681
2022
Q3 		$2M Buy
2,900
+1,100
+61% +$692K 0.01% 749
2022
Q2 		$1.06M Sell
1,800
-8,200
-82% -$5.33M 0.01% 982
2022
Q1 		$6.98M Sell
10,000
-52,700
-84% -$33.3M 0.02% 589
2021
Q4 		$39.6M Sell
62,700
-4,300
-6% -$2.64M 0.07% 259
2021
Q3 		$40.5M Buy
67,000
+10,000
+18% +$6.21M 0.08% 223
2021
Q2 		$31.8M Sell
57,000
-2,100
-4% -$1.06M 0.07% 248
2021
Q1 		$28M Sell
59,100
-9,700
-14% -$4.72M 0.08% 221
2020
Q4 		$33.2M Buy
68,800
+400
+0.6% +$216K 0.11% 152
2020
Q3 		$38.3M Buy
68,400
+24,400
+55% +$14.8M 0.2% 91
2020
Q2 		$27.4M Buy
44,000
+19,200
+77% +$10.9M 0.18% 99
2020
Q1 		$12.1M Sell
24,800
-51,700
-68% -$21.3M 0.19% 107
2019
Q4 		$28.7M Buy
76,500
+21,100
+38% +$7.1M 0.16% 147
2019
Q3 		$15.4M Buy
55,400
+1,000
+2% +$296K 0.11% 186
2019
Q2 		$17M Buy
54,400
+5,200
+11% +$1.73M 0.12% 182
2019
Q1 		$20.2M Buy
49,200
+38,000
+339% +$15.6M 0.19% 121
2018
Q4 		$4.18M Buy
11,200
+3,800
+51% +$1.39M 0.05% 282
2018
Q3 		$2.99M Buy
+7,400
New +$2.82M 0.03% 352

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Capstone Investment Advisors's REGN Position: Q1 2026 in Review

Capstone Investment Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 511 shares — an estimated $391K sold.

Capstone Investment Advisors first reported a position in REGN in Q3 2015 and held it in 25 quarters. The position peaked at $11.9M in Q4 2020. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Capstone Investment Advisors reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Capstone Investment Advisors sold 511 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $391K.
  • Capstone Investment Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2015 and held it in 25 quarters.
  • Capstone Investment Advisors's Regeneron Pharmaceuticals position peaked at $11.9M in Q4 2020.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Capstone Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.